NRG Therapeutics

Biotech · Private

Small molecule modulators of mitochondrial complex I for treating energy metabolism dysfunction in neurodegeneration

nrgtx.com →
Grants
—
No SBIR or STTR on record
Sector median: 1
Raised
—
No Form D on record
Contracts
—
No federal contracts on record
Patents
7
3 granted · 4 pending
Sector median: 2

Peer position

Biotech · 4373 companies · ranked on federal contract value
Biotech companies ranked by federal contract value
#CompanyContractsDisclosed equity
1321DRIVE THERAPEUTICS, L.L.C.——
1322Morphic Therapeutic——
1323LEFLORE TECHNOLOGIES LLC——
1324NRG Therapeutics——
1325Senseion Therapeutics, Inc.——
1326Sequegenics LLC——
1327Nellone Therapeutics, Inc.——

Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.

Patents

USPTO · 3 granted of 7
  • Novel Compoundsgranted
  • Inhibitors Of Mptpapplication
  • Acrylamide Derivativesgranted
  • Inhibitors Of Mptpgranted
  • Acrylamide Compoundsapplication
  • Novel Compoundsapplication
  • Pyridine Derivatives Which Act As Inhibitors Of Mptpapplication

Regulatory activity · Biotech

Sector-level, not company-level

Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.